Finance

Beta
Lists
LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
$1.88
0.00%
(0.00) 1D
$1.93
+2.66% (+0.050)
After hours
Closed: Jun 10, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LXRX...
Open
$1.85
High
$1.91
Low
$1.85
Mkt. cap
835.09M
Avg. vol.
2.72M
Volume
0.00
52-wk high
$2.53
52-wk low
$0.64
EPS
-$0.07
Beta
1.39
Shares outstanding
444.20M
No. of employees
81
Open
$1.85
High
$1.91
Low
$1.85
Mkt. cap
835.09M
Avg. vol.
2.72M
Volume
0.00
52-wk high
$2.53
52-wk low
$0.64
EPS
-$0.07
Beta
1.39
Shares outstanding
444.20M
No. of employees
81
Analyst outlook
Analyst Ratings
Based on 3 analysts giving stock ratings to LXRX in the past 3 months
Strong Buy
Buy
3
Hold
0
Sell
0
12 month forecast
Based on 3 Wall Street analysts offering 12 month price targets for LXRX in the last 3 months.
Highest
Current $1.88
$6.00 (+219.15%)
Average
$5.03 (+167.55%)
Lowest
$3.10 (+64.89%)
News stories
From sources across the web
Profile
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
About Lexicon Pharmaceuticals Inc
CEOLonnel Coats
Employees81
Founded1995
Headquarters-
SectorPharmaceutical industry
Websitelexpharma.com
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
/ -$0.04
0.00%miss
Revenue / Est. (USD)
21.10M / 9.78M
+115.69%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
28.87M
14.18M
5.49M
21.10M
Cost of goods sold
1.65M
18.77M
-43.32M
12.86M
Cost of revenue
1.65M
18.77M
-43.32M
12.86M
Research and development expenses
14.13M
-
54.83M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.35M
7.60M
8.76M
9.23M
Operating expense
23.48M
7.60M
63.59M
9.23M
Total operating expenses
25.13M
26.37M
20.27M
22.10M
Operating income
3.74M
-12.19M
-14.78M
-996.00K
Other non operating income
-
-
-
-
EBT including unusual items
3.25M
-12.77M
-15.53M
-1.04M
EBT excluding unusual items
3.25M
-12.77M
-15.53M
-1.04M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
3.25M
-12.77M
-15.53M
-1.04M
Net profit margin
11.27%
-90.04%
-282.72%
-4.94%
Earnings per share
0.01
-0.04
-0.04
-
Interest and investment income
1.83M
1.57M
1.28M
1.54M
Interest expense
-2.32M
-2.16M
-2.03M
-1.59M
Net interest expenses
-484.00K
-582.00K
-750.00K
-47.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
3.91M
-12.04M
-14.66M
-886.00K
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer